Vanguard Personalized Indexing Management
NVO

Vanguard Personalized Indexing Management’s Novo Nordisk NVO Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7M Buy
146,043
+33,867
+30% +$1.46M 0.06% 271
2026
Q1 		$4.12M Sell
112,176
-18,534
-14% -$878K 0.04% 366
2025
Q4 		$6.65M Sell
130,710
-7,962
-6% -$407K 0.06% 247
2025
Q3 		$7.7M Sell
138,672
-11,244
-8% -$658K 0.08% 211
2025
Q2 		$10.3M Buy
149,916
+22,191
+17% +$1.51M 0.12% 149
2025
Q1 		$8.87M Buy
127,725
+16,567
+15% +$1.37M 0.13% 136
2024
Q4 		$9.56M Sell
111,158
-12,316
-10% -$1.33M 0.14% 105
2024
Q3 		$14.7M Buy
123,474
+8,988
+8% +$1.2M 0.24% 68
2024
Q2 		$16M Buy
114,486
+13,288
+13% +$1.76M 0.31% 46
2024
Q1 		$13M Buy
101,198
+11,891
+13% +$1.42M 0.28% 58
2023
Q4 		$9.24M Buy
89,307
+335
+0.4% +$33.1K 0.24% 67
2023
Q3 		$8.09M Buy
88,972
+7,472
+9% +$658K 0.24% 63
2023
Q2 		$6.59M Buy
81,500
+6,164
+8% +$504K 0.2% 84
2023
Q1 		$5.98M Buy
75,336
+4,674
+7% +$331K 0.21% 86
2022
Q4 		$4.78M Buy
70,662
+8,634
+14% +$506K 0.2% 94
2022
Q3 		$3.09M Buy
62,028
+534
+0.9% +$28.6K 0.14% 136
2022
Q2 		$3.43M Buy
61,494
+17,296
+39% +$960K 0.16% 114
2022
Q1 		$2.45M Buy
44,198
+8,494
+24% +$436K 0.12% 156
2021
Q4 		$2M Buy
35,704
+7,382
+26% +$400K 0.12% 165
2021
Q3 		$1.36M Buy
28,322
+4,686
+20% +$227K 0.12% 163
2021
Q2 		$990K Sell
23,636
-25,750
-52% -$998K 0.1% 208
2021
Q1 		$1.67M Sell
49,386
-208
-0.4% -$7.41K 0.25% 81
2020
Q4 		$1.73M Buy
49,594
+1,934
+4% +$66.8K 0.38% 53
2020
Q3 		$1.66M Buy
47,660
+7,008
+17% +$234K 0.46% 47
2020
Q2 		$1.33M Sell
40,652
-2,224
-5% -$71K 0.6% 35
2020
Q1 		$1.29M Buy
+42,876
New +$1.28M 0.75% 28

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Vanguard Personalized Indexing Management's NVO Position: Q2 2026 in Review

Vanguard Personalized Indexing Management increased its Novo Nordisk (NVO) stake by 30% in Q2 2026, buying an estimated $1.46M and bringing the position to 146,043 shares worth $7M. The position accounts for 0.06% of the portfolio, ranked #271.

Vanguard Personalized Indexing Management first reported a position in NVO in Q1 2020 and has held it in 26 quarters since. The position peaked at $16M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Vanguard Personalized Indexing Management held 146,043 shares of Novo Nordisk worth $7M as of Q2 2026.
  • Vanguard Personalized Indexing Management bought 33,867 Novo Nordisk shares in Q2 2026, an estimated $1.46M.
  • Novo Nordisk made up 0.06% of Vanguard Personalized Indexing Management's portfolio in Q2 2026, its #271 holding.
  • Vanguard Personalized Indexing Management first reported a position in Novo Nordisk in Q1 2020 and has held it in 26 quarters since.
  • Vanguard Personalized Indexing Management's Novo Nordisk position peaked at $16M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q2 2026, filed 11 Aug 2026.